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Abstract
Background:  Cystinosis is an autosomal recessive disorder characterised by an intralysosomal
accumulation of cystine, and affected individuals progress to end-stage renal failure before the age
of ten. The causative gene, CTNS, was cloned in 1998 and the encoded protein, cystinosin, was
predicted to be a lysosomal membrane protein.
Results:  We have cloned the murine homologue of CTNS, Ctns, and the encoded amino acid
sequence is 92.6% similar to cystinosin. We localised Ctns to mouse chromosome 11 in a region
syntenic to human chromosome 17 containing CTNS. Ctns is widely expressed in all tissues tested
with the exception of skeletal muscle, in contrast to CTNS.
Conclusions:  We have isolated, characterised and localised Ctns, the murine homologue of CTNS
underlying cystinosis. Furthermore, our work has brought to light the existence of a differential
pattern of expression between the human and murine homologues, providing critical information
for the generation of a mouse model for cystinosis.
Background
Cystinosis is an autosomal recessive disorder character-
ised by an intralysosomal accumulation of cystine. The
underlying metabolic defect is a defective transport of
cystine across the lysosomal membrane [1, 2]. Cystine is
poorly soluble and forms crystals in the lysosomes as its
concentration increases. Affected individuals develop a
de Toni-Debré-Fanconi syndrome around six-eight
months and suffer a progressive decline of glomerular
filtration rate with end-stage renal failure occuring be-
fore the age of ten [3]. Other clinical signs, such as severe
growth retardation, ocular anomalies, diabetes, portal
hypertension, hypothyroidism as well as muscular and
neurological deterioration, appear due to the accumula-
tion of cystine in different organs [2, 4]. Two other less
severe forms (juvenile and ocular nonnephropathic)
have also been described and shown to be allelic by com-
plementation studies [5]. To date, the most effective
treatment of cystinosis is by the drug cysteamine which
reduces intracellular levels of cystine [6, 7]. However,
this treatment needs to be installed early on in the dis-
ease and at high doses, in order to be effective, and has a
number of undesirable side effects.
The cystinosis gene was mapped to a 1 cM interval on the
short arm of chromosome 17 between the markers
D17S1798 and D17S1828 [8]. The identification of a 57
kb [9] deletion, encompassing the marker D17S829 in
30% of affected individuals, allowed us to delineate the
gene interval to within the boundaries of this deletion
[10]. Via a combinaton of large-scale sequencing and
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exon-trapping techniques, a novel gene was identified in
the minimum deletion interval. The detection of various
mutations within the coding region of this gene, named
CTNS, validated it as responsible for all three forms of
cystinosis [11, 12, 13]. CTNS is composed of 12 exons and
the predicted translation start site is situated in exon 3.
The 2.7 kb CTNS transcript contains a 1101 bp open read-
ing frame (ORF) predicted to encode a protein of 367
amino acids, named cystinosin. Computer modelling us-
ing several hydrophobicity algorithms predicts that
cystinosin is an integral membrane-spanning protein
with seven transmembrane domains preceded by seven
potential N-glycosylation sites and an uncleavable signal
peptide at the amino-terminal end, and followed by a lys-
osomal targetting signal (GY-DQ-L) at the carboxy-ter-
minal end [10]. Taken together, these results suggest
that cystinosin is a lysosomal membrane protein. How-
ever, as yet, the exact role of cystinosin in cystine trans-
port is unknown and no animal model for cystinosis
exists. Thus, as a first step towards the creation of such a
model, we report here the isolation and characterisation
of the murine homologue of CTNS.
Results and Discussion
In order to identify the murine homologue of CTNS,
Ctns, a E11.5 mouse embryonic cDNA library (Clontech)
was screened with a probe spanning the entire ORF of
the human CTNS gene. Three overlapping cDNA clones
were isolated and completely sequenced. The recon-
structed sequence was homologous to a region of the hu-
man CTNS cDNA from base pair 565 to 2388. RACE
(rapid amplification of cDNA ends) PCR of an E13.5
adaptor ligated-cDNA library (kindly provided by D.
Weil, Institut Pasteur, Paris, France) was employed to
isolate the remainder of the 5' and 3' murine cDNA se-
quences using the Ctns cDNA primers 1.1 (5'-ACC AAG
AAC CGG ATC CTG GGG CA-3') and 2.1 (5'-GCC CTC
TTT CCT ACC TCC ACT TTC TGA-3'), coupled with the
adaptor primer AP1, and the nested primers 1.2 (5'-GCA
TTT TTC TCT CCG CGA GGC AC-3') and 2.2 (5'-GTC
AAT CAG TAA GCT GCC CTG GAT G-3'), coupled with
AP2, for the amplification of the 5' and 3' ends, respec-
tively (Marathon-Ready cDNA kit, Clontech).
The resulting consensus Ctns cDNA sequence is 2464 bp
long (GenBank accession number-AJ250670) with a 19
bp 5' non-coding region, a 1344 bp 3' non-coding region
and a 1101 bp ORF which, like CTNS, is predicted to en-
code a 367 aa protein. The Ctns translation start site,
which likewise lies within a Kozak consensus sequence
(GAGACCAatgA), and the polyadenylation site are pre-
dicted to be equivalent to those deduced for CTNS. All of
the 5' cDNA sequences amplified by RACE-PCR began at
the same position, i.e. with a sequence homologous to
the beginning of the CTNS exon 3. No sequences homol-
ogous to the CTNS untranslated exons 1 and 2 were de-
tected. Moreover, two EST clones (GenBank accession
numbers gi9165096 and gi6083297) containing 69 and
126 bp of upstream sequence, respectively, preceding the
beginning of the 5' non coding region that we identified,
also do not show homology with the CTNS exons 1 and 2.
At the nucleotide level, Ctns shows 83% homology with
CTNS for the ORF and 58.8% homology over 1257 bp for
the 3' untranslated region. The predicted encoded amino
acid sequence shows 83.9% identity and 92.6% similari-
ty with cystinosin (Figure 1A). The uncleavable signal
peptide, seven amino-terminal N-glycosylation sites,
seven transmembrane domains and lysosomal targetting
signal of cystinosin are conserved in the murine se-
quence.
In order to determine the exon/intron structure of Ctns,
the 129/Sv Ev Tac flor DNA genomic library (Stratagene)
was screened with a cDNA probe homologous to the
CTNS exons 7 to 12 and four clones were isolated. Se-
quence analysis of their inserts demonstrated that the
four overlapping clones spanned all the Ctns exons. The
Ctns gene spans 14 kb is composed of ten exons and its
exon/intron boundaries are identical to that of CTNS
(Figure 1B). A combination of Long Range PCR (Expand
Long Template PCR System, Boehringer Mannheim)
and sequencing permitted an estimation of intron sizes.
A comparison of the sizes of CTNS and Ctns introns
showed that, with the exception of the human introns 3
and 5, intron sizes were similar between both species
(Figure 1B).
The Ctns expression pattern was determined by hybridi-
sation of a probe spanning exons 4 and 5 to a Clontech
multiple tissue northern blot (MTN 7762-1). A transcript
with an expected size of 2.5 kb, highly expressed in kid-
ney and liver, less expressed in heart, and weakly ex-
pressed in brain, spleen, lung and testis was detected
(Figure 2); a proportionally faint approximately 4.4 kb
transcript could also be seen, reminiscent of the addi-
tional 4.4 kb CTNS transcript detected in human pancre-
as [10]. In contrast to the CTNS transcript, no expression
was detected in skeletal muscle (Fig. 2A) whereas hy-
bridisation with a β -actin cDNA control probe confirms
the loading of RNA for all tissues (Fig. 2B). A possible ex-
planation for this differential pattern of expression is
that the promoter situated upstream of the CTNS exon 1
has been lost during the course of evolution and the
working murine promoter does not direct the same tis-
sue expression, as has been proposed for IGF II [14].
Similarly, it is possible that sequences corresponding to
the CTNS exons 1 and 2 have also been lost during evolu-
tion or, alternatively, they exist in the form of pseudo-ex-
ons in the upstream genomic sequence. However, low
stringency hybridisation of the genomic clones contain-
ing the Ctns gene with a probe corresponding to the
CTNS exons 1 and 2, did not detect any homologous se-BMC Genomics (2000) 1:2 http://www.biomedcentral.com/1471-2164/1/2
Figure 1
Comparison of the human and murine CTNS genes and encoded products. (A) Alignment of the human and murine cystinosin
sequences. Asterisks indicate identical amino acid residues. Colons indicate residues of high similarity and fullstops residues of
low similarity. The uncleavable signal peptide is boxed, the N-glycosylation sites circled, the transmembrane domains overlined
and the lysosomal targetting signal is in bold. (B) Schematic representation of the gene structure of CTNS and Ctns. The exons
are indicated by solid boxes, the 3' non coding regions by a dashed box and the introns by a solid line. Ctns exon sizes are iden-
tical to those reported for CTNS [9]. Intron sizes are as follows: i) Ctns intron 1-3.5 kb; 2-1.5; 3-3; 4-0.127; 5-0.8; 6-0.095; 7-
1.1; 8-1.15 and 9-0.35. ii) CTNS intron 1-0.257 kb; 2-2.8; 3-8; 4-1.54; 5-6; 6-0.115; 7-1.2; 8-0.085; 9-1.2; 10-1.683 and 11-0.26.BMC Genomics (2000) 1:2 http://www.biomedcentral.com/1471-2164/1/2
quences thus providing support for the former hypothe-
sis. Moreover, comparison of 1.1 kb of genomic sequence
immediately upstream of the murine exon 1, which is hy-
pothesised to contain the Ctns promoter, with the CTNS
intron 2 sequence detected a region of significant homol-
ogy (66.7% over 306 bp). These results suggest the pos-
sible presence of an alternative CTNS promoter. Such
regions of homology between the regulatory sequences
of other human and murine homologue, such as WT1 or-
PAX-2, have also been described [15, 16].
The chromosomal localisation of the Ctns gene was de-
termined by PCR amplification of the mouse T31 irradi-
ation hybrid panel [17] with the primers LOC/1 (5'-TGT
GGC CCA TGG ACT TGA AG-3') and LOC/2 (5'-CAA TCT
GGC AGG CAC CTC A-3') situated in the 3' non-coding
region. Two point lod score analysis resulted in a signifi-
cant score of 5.37 and 5.36 with the chromosome 11
markers D11Mit279 and D11Mit7, respectively. A highly
significant score of 12.25 and 11.09 was obtained with the
ESTs AA589579 and R74628, respectively. R74628
maps distal to D11Mit7 and both of these markers are lo-
cated within two contigs which lie in the region of syn-
teny with human chromosome 17. Hence, this leads us to
assume that Ctns also lies in the region of chromosome
11 syntenic with chromosome 17 which contains the hu-
man CTNS gene.
Conclusions
Although, the encoded products of CTNS, the gene un-
derlying nephropathic cystinosis, and its murine homo-
logue,  Ctns, are highly conserved between man and
mouse, these genes have a differential expression pat-
tern. This information is crucial for the analysis of a
mouse model for cystinosis which, in the absence of a
spontaneous mouse mutant, we are currently generating
in order to study the pathogenesis of cystinosis in vivo.
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